FCGR2B and Graves disease: Similarly, interaction of maternal antibodies with FcγRIIB inhibits B-cell responses during pregnancy [36]; and the levels of FcγRIIB on naïve and marginal zone B cells are reduced in multiple sclerosis patients [37], on leukocytes in patients with systemic lupus erythematosus [38] and on circulatory B cells in Graves’ disease [39].